成立一年
2001年阶段
贷款 |活着总了
141.05美元最后提出了
$3.5M | 3年前缺失:棘波的产品演示和案例研究
促进你的产品提供技术买家。
达到1000年代的买家使用CB的见解来确定供应商,演示产品,德赢体育vwin官方网站做出购买决定。
缺失:棘波的产品&微分器
不要让你的产品被跳过。买家使用我们的供应商排名名单公司和驱动(rfp)请求建议。
专家集合包含棘波
专家集合是analyst-curated列表,突出了公司你需要知道的最重要的技术空间。
棘波中包含3专家集合,包括医疗设备。
医疗设备
11721件
公司发展医疗器械(每IMDRF的“医疗器械”的定义)。包括软件、lab-developed测试(LDTs)和组合产品。*列更新尽可能经常。
数字医疗
10530件
数字健康收藏品包括供应商开发软件、平台、传感器和机器人硬件,在医疗健康数据基础设施和tech-enabled服务。列表中不包括制药/生物制药、测序仪器,基因编辑和辅助技术。
它的健康
7901件
最新的棘波新闻
2023年4月5日
披露:Coric报告有股权溢价脊柱;作为一个顾问溢价的脊柱,脊柱波,Globus医疗、美敦力公司,诚信植入,SpineArt NuVasive;从棘波,获得版税Globus医疗、美敦力公司,诚信植入,Stryker脊椎和Surgalign;和资金为本研究机构从溢价的脊柱。主题添加到邮件提醒收到一封电子邮件在发布新文章时请提供您的电子邮件地址来接收电子邮件当张贴新文章。请稍后再试。如果你继续这个问题请联系customerservice@slackinc.com。回到Healio关键外卖:更换后方面有较高的临床成功率整体复合测量与融合。最低15点得以改善残疾指数支持更换后方面。结果显示使用后方面替代设备可以提供足够的减压和动态稳定与退行性腰椎管狭窄症患者脊椎前移。 Although lumbar stenosis with degenerative spondylolisthesis has historically been treated with decompression and fusion, Dom Coric, MD, said fusion stops motion at the facets, which may lead to increased stress at the levels above and below the fusion and can lead to increased risk of reoperation. However, he noted stabilization may be achieved and motion may be maintained with the use of decompression and an artificial facet. Data were derived from Coric D, et al. J Neurosurg Spine. 2022;doi:10.3171/2022.7.SPINE22536. Dom Coric “[With an artificial facet], now you have a situation where the nerves are free; the patients have done well; and you have maintained the motion, which is more of a natural phenomenon. And furthermore, you’re not placing this additional stress at the adjacent levels,” Coric, of Carolina Neurosurgery and Spine Associates and SpineFirst Atrium Health, told Healio. “So it’s a win-win situation, and that’s what the results of the study bore out: The patients that had decompression and dynamic stabilization with facet replacement did better than patients who had decompression and stabilization with the fusion.” Posterior facet replacement vs. fusion Coric and colleagues randomly assigned 249 patients with one-level symptomatic lumbar stenosis with grade I degenerative spondylolisthesis to undergo either posterior facet replacement with the Total Posterior Spine system (n=170; TOPS, Premia Spine) or transforaminal lumbar interbody fusion (n=79; TLIF). Researchers collected the Oswestry Disability Index (ODI) and VAS for back and leg pain preoperatively and at 6 weeks and at 3, 6, 12 and 24 months postoperatively. Researchers considered no reoperations, no device breakage, reduction of ODI of 15 points or more and no new or worsening neurological deficit as the primary outcome, with patients considered clinically successful if they met all four measures. Results showed 85% of patients in the TOPS group met the overall composite measure for clinical success compared with 64% of patients in the TLIF group. Researchers found a statistically significant difference in the percentage of patients reporting a minimum 15-point improvement in ODI, with 93% in the TOPS group vs. 81% in the TLIF group. However, researchers noted no statistically significant difference in the percentage of patients reporting a minimum 20-point improvement in VAS back pain and leg pain scores between the two groups. Rate of reintervention The TOPS group had a lower rate of surgical reintervention for facet replacement vs. the TLIF group (5.9% vs. 8.8%), according to results. From preoperatively to 24 months, researchers found patients in the TOPS group demonstrated maintenance of flexion/extension range of motion. “One-level TLIF is a common and well thought of operation. In other words, you would expect the success rate of that type of operation to be reasonably high. So, to show superiority to that, I think, is a positive,” Coric said. Read more about
棘波常见问题(FAQ)
棘波是何时成立的?
棘波成立于2001年。
棘波的总部在哪里?
棘波的总部位于3企业开车,谢尔顿。
棘波的最新一轮融资是什么?
棘波的最新一轮融资贷款。
棘波筹集了多少钱?
棘波筹集了总计141.05美元。
棘波的投资者是谁?
棘波的投资者包括工资保护计划,新企业Associates加州科技企业,罗盘EMP, 20 MB的合资伙伴和更多。
棘波的竞争对手是谁?
棘波的竞争对手包括Flowonix医疗、Vertos医疗、Avedro,公理,Gentis和12更多。
竞争对手比较棘波
脊髓修复恢复病人的生命交付新疗法脊柱健康管理解决未满足的需求。这些疗法是微创,早期干预和临床证实的结果。该公司正在与多样化,高度重视临床和科学顾问集团生物抑制剂系统的开发和获得监管部门的批准,专有resorbable生物和交付系统治疗慢性盘疼痛,基于固体科学和临床证据。
Theken圆盘,有限责任公司成立于2003年的设计,研发和制造脊柱关节成形术的产品,如eDisc,微电子人工椎间盘置换。
盘动力学发展DASCORTM盘关节成形术系统,一个创新的,微创核置换治疗病人患有慢性下腰痛引起的退行性椎间盘疾病(DDD)。
应用脊柱技术是脊柱公司专注于发展植入式动态稳定系统治疗慢性背部疼痛。
Gentis是微创的开发者,biomaterials-based产品旨在治疗脊椎的早期退化,导致背部疼痛。DiscCell公司的第一个专利产品,是一个突破可注射生物材料增强或取代病变的椎间盘的髓核。
Orthonicsis通过佐治亚理工学院的Venturlab项目创建的公司。Orthonics发展为骨科组织工程生物材料的应用。公司的核心技术与生物材料,允许在生长和粘附的骨头和软骨组织。最初的应用程序将椎间盘置换和aspinal阀瓣环的补丁。
发现正确的解决方案为您的团队
CB见解德赢体育vwin官方网站科技市场情报平台分析数百万数据点在供应商、产品、合作关系,专利来帮助您的团队发现他们的下一个技术解决方案。